AIM: To assess pharmacokinetic and pharmacodynamic interactions between naproxen (a non-steroidal anti-inflammatory drug) and apixaban (an oral, selective, direct factor-Xa inhibitor). METHOD: In this randomized, three period, two sequence study, 21 healthy subjects received a single oral dose of apixaban 10 mg, naproxen 500 mg or co-administration of both. Blood samples were collected for determination of apixaban and naproxen pharmacokinetics and pharmacodynamics (anti-Xa activity, international normalized ratio [INR] and arachidonic acid-induced platelet aggregation [AAI-PA]). Adverse events, bleeding time and routine safety assessments were also evaluated. RESULTS:Apixaban had no effect on naproxen pharmacokinetics. However, following co-administration, apixaban AUC(0,∞), AUC(0,t) and Cmax were 54% (geometric mean ratio 1.537; 90% confidence interval (CI) 1.394, 1.694), 55% (1.549; 90% CI 1.400, 1.713) and 61% (1.611; 90% CI 1.417, 1.831) higher, respectively. Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration. INR was within the normal reference range after all treatments. AAI-PA was reduced by approximately 80% with naproxen. Co-administration had no impact beyond that of naproxen. Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively). CONCLUSION: Co-administration of naproxen with apixaban results in higher apixaban exposure and appears to occur through increased apixaban bioavailability. The effects on anti-Xa activity, INR and inhibition of AAI-PA observed in this study were consistent with the individual pharmacologic effects of apixaban and naproxen.
RCT Entities:
AIM: To assess pharmacokinetic and pharmacodynamic interactions between naproxen (a non-steroidal anti-inflammatory drug) and apixaban (an oral, selective, direct factor-Xa inhibitor). METHOD: In this randomized, three period, two sequence study, 21 healthy subjects received a single oral dose of apixaban 10 mg, naproxen 500 mg or co-administration of both. Blood samples were collected for determination of apixaban and naproxen pharmacokinetics and pharmacodynamics (anti-Xa activity, international normalized ratio [INR] and arachidonic acid-induced platelet aggregation [AAI-PA]). Adverse events, bleeding time and routine safety assessments were also evaluated. RESULTS:Apixaban had no effect on naproxen pharmacokinetics. However, following co-administration, apixaban AUC(0,∞), AUC(0,t) and Cmax were 54% (geometric mean ratio 1.537; 90% confidence interval (CI) 1.394, 1.694), 55% (1.549; 90% CI 1.400, 1.713) and 61% (1.611; 90% CI 1.417, 1.831) higher, respectively. Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration. INR was within the normal reference range after all treatments. AAI-PA was reduced by approximately 80% with naproxen. Co-administration had no impact beyond that of naproxen. Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively). CONCLUSION: Co-administration of naproxen with apixaban results in higher apixaban exposure and appears to occur through increased apixaban bioavailability. The effects on anti-Xa activity, INR and inhibition of AAI-PA observed in this study were consistent with the individual pharmacologic effects of apixaban and naproxen.
Authors: Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez Journal: N Engl J Med Date: 2010-12-23 Impact factor: 91.245
Authors: Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245
Authors: Edelgard Lindhoff-Last; Meyer Michel Samama; Thomas L Ortel; Jeffrey I Weitz; Theodore E Spiro Journal: Ther Drug Monit Date: 2010-12 Impact factor: 3.681
Authors: John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin Journal: N Engl J Med Date: 2011-07-24 Impact factor: 91.245
Authors: Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: A Hillarp; F Baghaei; I Fagerberg Blixter; K M Gustafsson; L Stigendal; M Sten-Linder; K Strandberg; T L Lindahl Journal: J Thromb Haemost Date: 2011-01 Impact factor: 5.824